ASPO Abstracts
Interest and Uptake of MC1R Genetic Testing in Non-melanoma Skin Cancer Patients
Category: Behavioral Science & Health Communication, Early Detection & Risk Prediction
Conference Year: 2018
Abstract Body:
Non-melanoma skin cancer (NMSC) is common, and although rarely fatal, a history of NMSC is a risk factor for melanoma, the most fatal form of skin cancer. Many NMSC patients engage in skin cancer risk behaviors such as indoor tanning and insufficient use of protective clothing and sunscreen. Certain common variants of MC1R, a gene involved in the regulation of skin pigmentation, increase melanoma risk. Genetic testing for common melanoma risk variants, not currently offered in standard clinical practice, may have personal utility to increase risk knowledge and modify health behaviors. We are conducting a prospective cohort study examining interest, uptake, and behavioral utility of MC1R genetic testing among individuals with a history of NMSC (target N=75). Patients are approached during a follow-up visit to the dermatology clinic. Recruited participants complete a baseline assessment, are invited to log on to our study website to learn about MC1R testing, and then decide whether to accept or decline testing. Participants who accept testing return completed saliva test kits. DNA is extracted and sequenced in a CLIA laboratory. Test results are provided to participants in the form of written risk feedback. The participants’ responses to testing are assessed two weeks later. Skin cancer risk behaviors and attitudes are assessed three months after baseline. Of the 28 participants who have completed the baseline to date, 13 logged on the website and chose genetic testing. Current trends indicate that women and those who are not working are more likely to pursue testing. Of those who have chosen testing, 46% have a history of additional cancers, 85% have a history of sunburns, 67% do not tan easily, 31% report that their skin burns easily. Future data collection and analyses will determine sun protection behaviors and beliefs, utility of MC1R testing, impact on engagement with skin cancer risk behaviors, and reduction of burden of disease within public health. If results are promising, they will be used to shape acceptability of this test within this at-risk population. We acknowledge the funding support of the MSK Survivorship, Outcomes, and Risk Developmental Funds Award to Jennifer Hay and Irene Orlow (MPIs), and the MSK Cancer Center Core Grant P30 CA008748.
Keywords: genetic testing; melanoma prevention; skin cancer risk